Omeprazole
- Generic Name
- Omeprazole
- Brand Names
- Konvomep, Losec, Omeclamox, Omesec, Previdolrx Analgesic Pak, Prilosec, Talicia, Yosprala, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3O3S
- CAS Number
- 73590-58-6
- Unique Ingredient Identifier
- KG60484QX9
- Background
Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs . Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults .
- Indication
Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes:
• Treatment of active duodenal ulcer in adults
• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer
recurrence in adults
• Treatment of active benign gastric ulcer in adults
• Reduction of risk of upper gastrointestinal (GI) bleeding in critically ill adult patients.
• Treatment of symptomatic gastroesophageal reflux disease (GERD) in
patients 1 year of age and older
• Treatment of erosive esophagitis (EE) due to acid-mediated GERD in
patients 1 month of age and older
• Maintenance of healing of EE due to acid-mediated GERD in patients 1
year of age and older
• Pathologic hypersecretory conditions in adults
- Associated Conditions
- Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Osteoarthritis (OA), Rheumatoid Arthritis, Upper GI Bleeding, Zollinger-Ellison Syndrome, Benign, active Gastric Ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Multiple endocrine adenomas
The Possible Protective Role of Omeprazole Against Oxaliplatin Induced Neuropathy in Cancer Patients
- Conditions
- Chemotherapy Induced Peripheral Neuropathy
- Interventions
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Aya Mohamed Sadek Elsaid
- Target Recruit Count
- 46
- Registration Number
- NCT05680870
Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 31
- Registration Number
- NCT05635110
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, Australia
A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 14
- Registration Number
- NCT05599828
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc, Dallas, Texas, United States
Study to Evaluate the Drug-drug Interaction Effect of Omeprazole on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 14
- Registration Number
- NCT05581992
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc, Daytona Beach, Florida, United States
A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT05517928
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy Volunteers
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 16
- Registration Number
- NCT05497557
- Locations
- 🇺🇸
Labcorp Clinical Research Unit Inc., Dallas, Texas, United States
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Advanced Solid TumorsMetastatic Solid Tumors
- Interventions
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 232
- Registration Number
- NCT05487235
- Locations
- 🇦🇷
Sanatorio Allende, Cordoba, Argentina
🇦🇷Fundacion CORI para la Investigacion y Prevencion del Cancer, La Rioja, Argentina
🇦🇷Centro Medico IPAM, Rosario, Argentina
A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy Participants
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 19
- Registration Number
- NCT05468164
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study of Imlunestrant (LY3484356) in Female Healthy Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2022-11-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 113
- Registration Number
- NCT05444556
- Locations
- 🇺🇸
Altasciences Clinical Los Angeles, Inc, Cypress, California, United States
🇺🇸Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸ICON Early Phase Services, San Antonio, Texas, United States
Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 59
- Registration Number
- NCT05438303
- Locations
- 🇺🇸
Research Site, Berlin, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.